FI923915A0 - Foerbaettrade kimera toxiner. - Google Patents

Foerbaettrade kimera toxiner.

Info

Publication number
FI923915A0
FI923915A0 FI923915A FI923915A FI923915A0 FI 923915 A0 FI923915 A0 FI 923915A0 FI 923915 A FI923915 A FI 923915A FI 923915 A FI923915 A FI 923915A FI 923915 A0 FI923915 A0 FI 923915A0
Authority
FI
Finland
Prior art keywords
fragment
toxin
diphtheria toxin
chimeric
domain
Prior art date
Application number
FI923915A
Other languages
English (en)
Other versions
FI923915A (fi
Inventor
Diane Williams
Original Assignee
Univ Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI923915(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Hospital filed Critical Univ Hospital
Publication of FI923915A publication Critical patent/FI923915A/fi
Publication of FI923915A0 publication Critical patent/FI923915A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
FI923915A 1990-03-02 1992-09-01 Foerbaettrade kimera toxiner. FI923915A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48860890A 1990-03-02 1990-03-02
US53743090A 1990-06-13 1990-06-13
PCT/US1991/001282 WO1991013090A1 (en) 1990-03-02 1991-02-28 Improved chimeric toxins

Publications (2)

Publication Number Publication Date
FI923915A FI923915A (fi) 1992-09-01
FI923915A0 true FI923915A0 (fi) 1992-09-01

Family

ID=27049417

Family Applications (1)

Application Number Title Priority Date Filing Date
FI923915A FI923915A0 (fi) 1990-03-02 1992-09-01 Foerbaettrade kimera toxiner.

Country Status (11)

Country Link
US (6) US5616482A (fi)
EP (1) EP0517829B2 (fi)
JP (1) JP3311346B2 (fi)
AT (1) ATE200493T1 (fi)
CA (1) CA2076678C (fi)
DE (1) DE69132581T3 (fi)
DK (1) DK0517829T4 (fi)
ES (1) ES2155821T5 (fi)
FI (1) FI923915A0 (fi)
GR (1) GR3036081T3 (fi)
WO (1) WO1991013090A1 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
EP1687016A4 (en) 2003-11-25 2009-07-29 Anjin Corp GENETIC VARIANT OF DIPHTHERIC TOXIN
RU2006138235A (ru) * 2004-03-31 2008-05-10 Трофоджен, Инк. (Us) Суперагонисты человеческих гликопротеиновых гормонов и способы их применения
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
NZ575134A (en) * 2006-08-28 2012-06-29 Clinuvel Pharmaceuticals Ltd Method for reducing incidence or rate of development of skin cancers and related conditions using alpha-msh analogue
EP3520806B1 (en) 2006-09-07 2024-03-20 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
WO2011047135A2 (en) * 2009-10-14 2011-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bladder cancer
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
US10988512B2 (en) 2016-03-10 2021-04-27 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20220062390A1 (en) 2020-08-26 2022-03-03 Dr. Reddy's Laboratories Sa Methods of treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US4468382A (en) * 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein
US4830962A (en) * 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
EP0170697B1 (en) * 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
NZ212312A (en) * 1984-06-07 1988-09-29 John Richard Murphy Hybrid protein comprising fragments of diphtheria toxin and part of cell-specific ligand; and fused gene therefor
AU6733287A (en) * 1985-11-13 1987-06-02 Murphy, J.R. Cys codon-modified dna
IN165717B (fi) * 1986-08-07 1989-12-23 Battelle Memorial Institute
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Also Published As

Publication number Publication date
US5863891A (en) 1999-01-26
DK0517829T3 (da) 2001-05-07
DK0517829T4 (da) 2008-03-03
AU7493191A (en) 1991-09-18
AU661819B2 (en) 1995-08-10
US5763250A (en) 1998-06-09
EP0517829A4 (en) 1993-05-05
US5932471A (en) 1999-08-03
CA2076678A1 (en) 1991-09-03
DE69132581T2 (de) 2002-04-11
WO1991013090A1 (en) 1991-09-05
JPH06500531A (ja) 1994-01-20
US5703039A (en) 1997-12-30
FI923915A (fi) 1992-09-01
ES2155821T3 (es) 2001-06-01
EP0517829A1 (en) 1992-12-16
US5616482A (en) 1997-04-01
EP0517829B1 (en) 2001-04-11
ATE200493T1 (de) 2001-04-15
US5677148A (en) 1997-10-14
JP3311346B2 (ja) 2002-08-05
DE69132581T3 (de) 2008-07-17
CA2076678C (en) 1999-09-28
ES2155821T5 (es) 2008-04-16
DE69132581D1 (de) 2001-05-17
EP0517829B2 (en) 2007-12-26
GR3036081T3 (en) 2001-09-28

Similar Documents

Publication Publication Date Title
NO840089L (no) Hybrid-proteiner
FI923915A (fi) Foerbaettrade kimera toxiner
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
KR920701452A (ko) 프라세싱 부위에 인접한 음전하를 띤 아미노산을 함유하는 이스트 프라세싱 시스템
ATE278708T1 (de) Conotoxin peptid pviia
EP0185076A4 (fi)
Graf et al. Cathepsin D generates γ-endorphin from β-endorphin
SE8204811L (sv) Dna-fragment innefattande en signalsekvens
Greenfield et al. Toxin conjugates.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: BOSTON MEDICAL CENTER CORPORATION